8QPR

SARS-CoV-2 S protein bound to human neutralising antibody UZGENT_G5

8QPR の概要

• エントリーDOI: 10.2210/pdb8qpr/pdb
• EMDBエントリー: 18560
• 分子名称: Spike glycoprotein,Fibritin, IgG light chain - FAB, IgG heavy chain - FAB, ... (5 entities in total)
• 機能のキーワード: neutralizing antibody, spike protein, viral protein
• 由来する生物種: Severe acute respiratory syndrome coronavirus 2 (2019-nCoV, SARS-CoV-2); 詳細
• タンパク質・核酸の鎖数: 3
• 化学式量合計: 192675.81

構造登録者

Remaut, H.,Reiter, D.,Vandenkerckhove, L.,Acar, D.D.,Witkowski, W.,Gerlo, S. (登録日: 2023-10-03, 公開日: 2024-01-31, 最終更新日: 2024-11-06)

主引用文献

Acar, D.D.,Witkowski, W.,Wejda, M.,Wei, R.,Desmet, T.,Schepens, B.,De Cae, S.,Sedeyn, K.,Eeckhaut, H.,Fijalkowska, D.,Roose, K.,Vanmarcke, S.,Poupon, A.,Jochmans, D.,Zhang, X.,Abdelnabi, R.,Foo, C.S.,Weynand, B.,Reiter, D.,Callewaert, N.,Remaut, H.,Neyts, J.,Saelens, X.,Gerlo, S.,Vandekerckhove, L.
Integrating artificial intelligence-based epitope prediction in a SARS-CoV-2 antibody discovery pipeline: caution is warranted.
Ebiomedicine, 100:104960-104960, 2024

PubMed Abstract: SARS-CoV-2-neutralizing antibodies (nABs) showed great promise in the early phases of the COVID-19 pandemic. The emergence of resistant strains, however, quickly rendered the majority of clinically approved nABs ineffective. This underscored the imperative to develop nAB cocktails targeting non-overlapping epitopes.

PubMed: 38232633
DOI: 10.1016/j.ebiom.2023.104960

実験手法

ELECTRON MICROSCOPY (3.8 Å)